Vinigrol, a novel antihypertensive and platelet aggregation inhibitory agent produced by a fungus, Virgaria nigra. II. Pharmacological characteristics.
Vinigrol, a novel diterpene produced by Virgaria nigra, was tested orally in conscious spontaneously hypertensive rats (SHR) to confirm its antihypertensive activity. Vinigrol (2 mg/kg, po) decreased the mean arterial blood pressure of SHR by approximately 15% for at least 6 hours. Vinigrol induced contraction of rat aortic smooth muscle preparation at 1.5 X 10(-7) M, the contraction was blocked by nilvadipine, a Ca2+ entry blocker, but was not inhibited by prazosin or yohimbine. Radio-receptor binding assay of alpha adrenoceptors of rat brain membrane revealed that vinigrol had no affinity for these receptors.
Ando
T
T
Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Ibaraki, Japan.
Yoshida
K
K
Okuhara
M
M
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D004224:Diterpenes / Q000494:pharmacology*; D066298:In Vitro Techniques; D008297:Male; D003904:Mitosporic Fungi / Q000032:analysis; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D051381:Rats; D011918:Rats, Inbred SHR; D011919:Rats, Inbred Strains; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects; D014661:Vasoconstriction / Q000187:drug effects
D000959:Antihypertensive Agents; D004224:Diterpenes; D010975:Platelet Aggregation Inhibitors; D011942:Receptors, Adrenergic, alpha; C055112:vinigrol; D002118:Calcium